Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

912 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods.
Fukui T, Rahman M, Hayashi K, Takeda K, Higaki J, Sato T, Fukushima M, Sakamoto J, Morita S, Ogihara T, Fukiyama K, Fujishima M, Saruta T; CASE-J Study Group. Fukui T, et al. Among authors: saruta t. Hypertens Res. 2003 Dec;26(12):979-90. doi: 10.1291/hypres.26.979. Hypertens Res. 2003. PMID: 14717341 Free article. Review.
Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.
Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T; Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Ogihara T, et al. Among authors: saruta t. Hypertension. 2008 Feb;51(2):393-8. doi: 10.1161/HYPERTENSIONAHA.107.098475. Epub 2008 Jan 2. Hypertension. 2008. PMID: 18172059 Clinical Trial.
The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial.
Ogihara T, Nakao K, Fukui T, Fukiyama K, Fujimoto A, Ueshima K, Oba K, Shimamoto K, Matsuoka H, Saruta T; CASE-J Trial Group. Ogihara T, et al. Among authors: saruta t. Hypertens Res. 2008 Aug;31(8):1595-601. doi: 10.1291/hypres.31.1595. Hypertens Res. 2008. PMID: 18971535
Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients.
Ogihara T, Saruta T, Rakugi H, Shimamoto K, Ito S, Matsuoka H, Horiuchi M, Imaizumi T, Takishita S, Higaki J, Katayama S, Saito I, Shimada K; COLM study investigators. Ogihara T, et al. Among authors: saruta t. Hypertens Res. 2009 Feb;32(2):163-7. doi: 10.1038/hr.2008.31. Epub 2009 Jan 23. Hypertens Res. 2009. PMID: 19262477 Clinical Trial.
Relationship between the achieved blood pressure and the incidence of cardiovascular events in Japanese hypertensive patients with complications: a sub-analysis of the CASE-J trial.
Ogihara T, Saruta T, Rakugi H, Fujimoto A, Ueshima K, Yasuno S, Oba K, Takeda K, Higaki J, Nakao K; CASE-J trial Group. Ogihara T, et al. Among authors: saruta t. Hypertens Res. 2009 Apr;32(4):248-54. doi: 10.1038/hr.2008.34. Hypertens Res. 2009. PMID: 19347033 Clinical Trial.
912 results